Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Mesoblast Limited — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $60.41 (market cap $77.43B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 44.2× Mesoblast Limited's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.43% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 107 Days and Mesoblast Limited for 15 Days on average.
| MDLZ | MESO | |
|---|---|---|
Market Cap | $77.43B | $1.75B |
Volume | 7,695,104 | 239,027 |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $20.96 |
52-Week Low | $51.51 | $13.19 |
Typical Hold Time | 107 Days | 15 Days |
Enterprise Value | $97.78B | $1.83B |
Dividend Yield | 3.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $60.67, up 2.17% with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats with Q2 2026 EPS of $0.73 exceeding expectations. Recent dividend increase to $0.52 per share and positive cash flow trends support the investment case. Valuation metrics include P/E of 22.22 and P/S of 1.97, while revenue growth continues with 2025 revenue reaching $38.54 billion.
MDLZ presents a compelling opportunity with 76% analyst buy ratings and $70.29 consensus price target representing 16% upside. The company demonstrates pricing power and emerging market momentum, though cocoa cost pressures and margin compression from 13.76% in 2023 to 6.36% in 2025 remain key watchpoints. Strong brand portfolio and defensive characteristics provide stability amid market volatility.
Mesoblast (MESO) trades at $13.75, down 1.36% with bearish technical signals despite recent FDA approval for its Ryoncil potency assay. The company shows significant revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent milestones include completing Phase 3 trials for chronic back pain treatment, positioning the biotech firm for potential market expansion in the $10 billion back pain market.
Investment outlook balances promising commercial progress against persistent financial losses. The stock offers speculative growth potential through FDA-approved therapies and pipeline developments, but carries substantial risk from ongoing cash burn and competitive pressures in the regenerative medicine space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
